My immediate reaction is that that depends on the specific objectives of the advocacy organizations, as well as who they’re aiming to influence.
For example, the article mentions the patent waiver a lot. While this is (I think) a point of difference between Manya and me, I’m currently unsure (50-50 split, in fact) about the sign of the effect of the patent waiver, and pretty convinced the magnitude is small (and that it obscures the deeper problems with vaccine supply).
Thanks for the link! I will look into this soon.
My immediate reaction is that that depends on the specific objectives of the advocacy organizations, as well as who they’re aiming to influence.
For example, the article mentions the patent waiver a lot. While this is (I think) a point of difference between Manya and me, I’m currently unsure (50-50 split, in fact) about the sign of the effect of the patent waiver, and pretty convinced the magnitude is small (and that it obscures the deeper problems with vaccine supply).